chsyys/ShutterStock
Dasa (DASA3) revealed on Tuesday (30) that it has entered into two agreements to sell its businesses in Argentina — Diagnosis Maipú by Imágenes S.A., Medical Investment S.A., and Mantris subsidiary, focusing on occupational medicine and integrated health management.
The transaction involved a total amount of R$704.8 million, with R$700.8 million paid upfront. As part of the deal with Mantris, R$4 million were set aside for three years to address any potential liabilities before finalizing the transaction.
In the 12-month period of 2024, the companies generated an EBITDA of R$ 118 million, as reported by InfoMoney.
Dasa’s strategic plan includes sales to emphasize its core focus on Diagnostics, while divesting non-strategic assets such as Dasa Companies.
Dasa (DASA3) decreases losses to R$ 111 million in the first quarter.
Dasa (DASA3), a diagnostic medicine company, announced a net loss of R$ 111 million in the first quarter of 2025. This loss marks an improvement from the previous year’s accumulated loss of R$ 176 million. The financial report, released on Wednesday (14), includes the performance of the company’s hospital unit, which was separated in a joint venture with Amil.
The Ebitda profits from Dasa in the first quarter between January and March totaled R$ 708 million, showing an 11% increase compared to the previous year. This achievement was attributed to improved operational efficiency and cost control measures, marking the best first-quarter performance as per the management.
Dasa’s total revenue for the quarter reached R$3.826 billion, showing a 3% increase compared to the previous year. The diagnostic division generated R$1.921 billion in revenue during the period, marking a 6% growth from the same period in 2024. However, the hospital and oncology sector experienced a slight annual decline of 1%, resulting in a net revenue loss of R$1.905 billion after tax deductions.
- Businesses in the Sack
- Business
- Dasa (DASA3)
